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cDivision of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, CanadaAbstractPurpose: To evaluate the imaging features on high-resolution computed tomography (HRCT) of the chest and the clinical parameters that are
associated with pulmonary hypertension in systemic sclerosis. We specifically investigated whether main pulmonary artery (MPA) diameter
and burden of lung fibrosis are predictors of pulmonary hypertension in these patients.
Methods:We retrospectively retrieved the database information of patients with systemic sclerosis seen at our hospital between January 2007
and December 2008. A total of 75 patients had HRCT of the chest, pulmonary function testing (PFT), and echocardiography within 6 months
of each other. The echocardiography images were reviewed by a level-3 echocardiographer, and 29 cases were excluded because of
suboptimal evaluation of pulmonary artery (PA) pressure. Peak PA pressures and PFT of the remaining 46 cases (43 women and 3 men) were
charted. The PFT included total lung capacity (TLC), diffusion capacity of lung for carbon monooxide (DLCO) and the ratio of forced
expiratory volume in one second and forced vital capacity (FEV1/FVC). The HRCT of the chest of each patient was read by a chest
radiologist. The extent of ground glass, reticulation, and honeycombing was objectively scored. The maximum diameter of the main
pulmonary artery (MPAD) and ascending aorta were measured. The ratio of main pulmonary artery diameter and ascending aortic diameter
(MPAD/AD) and ratio of main pulmonary artery diameter and body surface area (MPAD/BSA) were also calculated.
Results: Statistical analysis done by using a multivariate model showed that the calculated fibrotic score strongly correlated with peak PA
pressures (P < .001). MPAD (P ¼ .0175), and the ratio MPAD/AD (P ¼ .0102) also showed a statistically significant correlation with peak PA
pressures. By using stepwise regression analysis, the fibrotic score was found to be the most reliable independent predictor of pulmonary
hypertension.
Conclusion: HRCT-determined severity and extent of pulmonary fibrosis may be helpful in screening for pulmonary hypertension in patients
with systemic sclerosis.Re´sume´Objet: E´valuer les caracte´ristiques d’imagerie de la tomodensitome´trie haute re´solution (TDM-HR) du thorax et les parame`tres cliniques
associe´s a` l’hypertension pulmonaire dans les cas de scle´rodermie ge´ne´ralise´e. Nous avons tout particulie`rement cherche´ a` savoir si le
diame`tre de l’arte`re pulmonaire principale (APP) et la charge de la fibrose pulmonaire constituent des facteurs pre´dictifs de l’hypertension
pulmonaire chez ces patients.
Me´thodes: De fac¸on re´trospective et a` partir de notre base de donne´es, nous avons se´lectionne´s les patients atteints de scle´rodermie ge´n-
e´ralise´e qui ont e´te´ traite´s a` notre hoˆpital entre janvier 2007 et de´cembre 2008. En tout, 75 patients ont be´ne´ficie´ d’une TDM-HR thoracique,
une exploration fonctionnelle respiratoire et d’une e´chocardiographie dans un de´lai de six mois tout au plus entre chaque test. Les images de
l’e´chocardiographie ont e´te´ examine´es par un technologue en e´chographie cardiaque de niveau 3, et 29 cas ont e´te´ exclus en raison d’une
e´valuation sous-optimale de la pression arte´rielle pulmonaire. Les pics de pression arte´rielle pulmonaire et l’exploration fonctionnelle
respiratoire (VEMS/CVF, CPT et DLCO) des 46 autres patients (43 femmes et 3 hommes) ont e´te´ repre´sente´s sous forme de graphique. La
TDM-HR thoracique de chaque patient a e´te´ examine´e par un radiologue thoracique. L’e´tendue de l’aspect en verre de´poli, de la re´ticulation* Address for correspondence: Jonathon Leipsic, MD, Department of
Radiology, St Paul’s Hospital, 1081 Burrard Street, Vancouver, British
Columbia V6Z 1Y6, Canada.
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292 A. K. Pandey et al. / Canadian Association of Radiologists Journal 61 (2010) 291e296et des images en rayon de miel ont e´te´ note´e de fac¸on objective. Le diame`tre maximal de l’APP et de l’aorte ascendante a e´te´ mesure´. Les
ratios APP/aorte et APP/surface corporelle ont e´galement e´te´ calcule´s.
Re´sultats: L’analyse statistique effectue´e a` l’aide d’un mode`le multivarie´ a de´montre´ qu’il existait une forte corre´lation entre le score de fibrose
calcule´ et les pics de pression arte´rielle pulmonaire (P< 0,001). Le diame`tre de l’APP (P¼ 0,0175) et le ratio APP/aorte (P¼ 0,0102) ont eux
aussi montre´ une corre´lation statistiquement importante avec les pics de pression arte´rielle pulmonaire. A` la suite d’une analyse par re´gression
pas a` pas, nous avons constate´ que le score de fibrose constitue le facteur pre´dictif le plus fiable d’hypertension pulmonaire.
Conclusion: L’e´valuation de la gravite´ et de l’e´tendue de la fibrose pulmonaire graˆce a` la TDM-HR peut se re´ve´ler utile aux fins du de´pistage
de l’hypertension pulmonaire chez les patients atteints de scle´rodermie ge´ne´ralise´e.
 2010 Canadian Association of Radiologists. All rights reserved.
Key Words: Pulmonary hypertension; Scleroderma; Fibrotic score; High-resolution computed tomography
Systemic sclerosis (SSc) is a complex, chronic, multi- years old, with a range of 23e83 years. From the echocardio-
system autoimmune connective tissue disorder that
frequently involves the pulmonary system. More than 90% of
patients with SSc have evidence of interstitial lung disease
(ILD) at autopsy, and 40% of patients with SSc demonstrate
abnormal PFTs [1]. Pulmonary hypertension (PH) is another
important pulmonary complication of SSc. It is a major cause
of mortality in patients with SSc, independent of ILD [2].
Although there have been significant advances in the treat-
ment of PH related to SSc, the prognosis remains poor, with
a median survival of 2e3 years [3]. The clinical and radio-
graphic determinants of PH in these patients are not well
known. Previous studies [4e6] that involved patients with
diverse lung parenchymal and pulmonary vascular diseases
suggested that the diameter of the main pulmonary artery
(MPA) as measured on computed tomography (CT) of the
chest can be used to predict PH. However, other studies [7e
11] questioned the reliability of the MPA diameter as
a determinant of PH. We planned this retrospective study
with the primary aim to determine the CT features and the
clinical parameters that predict PH in patients with SSc.
Specifically, we tested the hypothesis that the MPA diameter
correlates with PA pressure in patients with SSc.Materials and Methods
The study received ethics approval from the local research
ethics board. A hospital database (St Paul’s Hospital, Van-
couver, Canada) of 95 patients with a diagnosis of sclero-
derma who were seen between January 2007 and December
2008 at the respiratory clinic was reviewed. All subjects met
current American College of Rheumatology criteria for the
diagnosis of SSc [12]. We included only those patients who
underwent at least 1 echocardiogram, pulmonary function
testing (PFT), and high-resolution CT (HRCT) of the thorax
within 6 months of each other. Twenty cases were excluded
because the time interval between their HRCT of the chest,
PFT, and echocardiography was more than 6 months. The
echocardiographic images of the remaining 75 cases were all
read by a level-3 echocardiographer (R.M.). Twenty-nine
cases were excluded because the echocardiographic images
were suboptimal for assessing peak systolic PA pressure,
which left a total of 46 cases (43 women and 3 men) for the
present analysis. The mean age of the study subjects was 55graphic images, the peak systolic PA pressures were abstracted
and fromPFTs, the total lung capacity (TLC), the ratio of forced
expiratory volume in 1 second and forced vital capacity (FEV1/
FVC) and the diffusion capacity of lung for carbon monoxide
(DLCO) were abstracted. For the TLC and DLCO measure-
ments a body box was used. The National Health and Nutrition
Examination Study III population data were used as criterion
standards for the calculation of the PFTs.CT TechniqueAll the patients in the study underwent HRCT of the chest
on a multidetector CT unit (16 detector rows LightSpeed or
64 detector VCT; GE Medical Systems, Milwaukee, WI).
The CT parameters included slice thickness of 1.25 mm,
taken at an interval of 0.8 mm at 100 kV and 360 mA. The
pitch used was 0.984:1. The scanning was performed through
the entire thorax while the subject was in a supine position.
The CT examinations were performed during inspiration
with breath holding. Images were reconstructed with an
edge-enhancing algorithm and field of view of the widest
outer rib to outer rib dimension. Lung windows with a width
of 1500 HU and a level of 700 HU were applied.CT ReadingThe CTs were read by an experienced chest radiologist
with 4 years of postfellowship chest-imaging experience
(J.L.) who was blinded to clinical and laboratory data. The
amount of ground glass, lung fibrosis, and honeycombing
(HC) was quantified on each of the studies by using
following radiographic definitions [11]. Ground glass opacity
(GGO) was defined as a hazy parenchymal opacity with
preservation of bronchial and vascular margins. Lung fibrosis
was defined as interlobular septal thickening, intralobular
lines, traction bronchiectasis, and traction bronchiolectasis.
HC was defined as clustered air-filled cysts with well-defined
walls. Scoring of each lobe was performed by using a Likert
scale (in which 0, absent; 1, 1%e25%; 2, 26%e50%; 3,
51%e75%; and 4, 76%e100%) based on the method
established by Kazerooni et al [13]. The mean score of all 5
lobes was determined for each category of parenchymal
abnormality: fibrosis (CT-determined fibrosis score [CT-fib]),
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HC (CT-determined honeycomb score [CT-hc]). Ground
glass score for each lobe was aggregated to produce a total
CT-gg score. The total CT-fib and total CT-hc scores were
similarly computed by summing the scores from all 5 lobes.
All of these values were added together to yield a CT-
determined total perfusion score (CT-tot ¼ CT-fib þ CT-gg
D CT-hc). For each lobe, the score was also weighted by
the relative size of that lobe (right upper lobe, 0.0935; right
middle lobe, 0.0935; right lower lobe, 0.363; left upper lobe,
0.155; and left lower lobe, 0.297) [11]. These scores were
summed to yield weighted scores for ground glass (wCT-gg),
fibrosis (wCT- fib), HC (wCT-hc), and total perfusion (wCT-tot).
MPA diameter (MPAD) was measured at its widest
dimension at the level of its bifurcation on an axial supine
scan. At the same level, the widest portion of the ascending
aortic diameter (AD) above the sinus of Valsalva in the
tubular aorta was also measured and MPAD/AD ratio were
calculated for each patient. Body surface area (BSA) was
calculated by using the formula: BSA ¼ 0.00718 
weight0.425  height 0.725 [11]. Normalized MPAD was also
charted for each case by calculating MPAD/BSA ratio.Statistical AnalysisTable 1
Demographics and pulmonary function tests of the database cohort
Patients
included
Patients
excluded P value
No. subjects 46 49
Age, y 55.3 12.7 53.8  15.6 .593
Women, no. (%) 43 (93) 54 (79) .059
BMI, kg/m2 25.1  4.8 25.3  6.4 .891
FEV1/FVC, % 82.2  8.7 77.9  11.2 .051
TLC, L 4.24  1.08 4.56  1.42 .057
DLCO/VA, ml/mm Hg/min/L 3.34  0.88 3.53  0.75 .267
SD ¼ standard deviation; BMI ¼ body mass index; FEV1 ¼ forced expi-
ratory volume in 1 s; FVC ¼ forced vital capacity; TLC ¼ total lung
capacity; DLCO/VA ¼ diffusing capacity of the lung for carbon monoxide
corrected for alveolar volume.Continuous variables are expressed as mean (standard
deviation [SD]) and dichotomous variables are expressed as
a number (% of total). Because the peak systolic pulmonary
arterial (PA) pressure was not normally distributed and to
mitigate the effects of extreme outliers, this variable was log-
transformed for analysis. Univariate linear regression was
used to assess the relationship of peak systolic PA pressure to
demographic (age and sex), clinical (PFT parameters) and
imaging parameters. We then used multivariate linear
regression modelling to adjust for age and sex in all of the
above relationships. To determine which of the demographic,
clinical, and imaging parameters was most closely associated
with the peak systolic PA pressure, we performed a stepwise
regression analysis. In this model, we used 2 tuning param-
eters (SLENTRY ¼ 0.25 and SLSTAY ¼ 0.15). Thus, each of
the variables with an F statistic significant at P ¼ .25 was
added one by one to the model until all the variables were
exhausted. The model then evaluated all of these ‘‘signifi-
cant’’ variables collectively and deleted those variables that
failed to achieve an F statistic significant at the P ¼ .15 level.
For the variables that remained in the final model, a partial R-
square (the extent of variability of the peak systolic PA
pressure explained), andMallow’s C (p) values were reported.
The latter is a measure of ‘‘goodness of fit’’ of the model, with
low values indicating good fit, whereas high values indicate
poor fit. All analyses were 2-tailed and were conducted by
using SAS version 9.1 (SAS Institute, Cary, NC).
Results
The study sample was representative of the cohort (n ¼
95) of patients with scleroderma, because there was nosignificant difference between the study group (n ¼ 46) and
excluded group (n ¼ 49) with respect to age, sex, body mass
index, and PFTs (see Table 1).
The mean peak systolic PA pressure was 35.7 mmHg, with
SD of 12.5 mm Hg. If we defined PH as a peak systolic PA
pressure >40 mm Hg on echocardiography, then 13 patients
of 46 cases had PH. The MPAD of all 46 patients was 27.9 
4 mm. HC was seen in only 8 cases (17%) (CT-hc ¼ 0.21 
0.62). Fibrosis was observed in 33 of a total of 46 cases
(72%), with CT-fib being 0.90  0.94. Ground glass was the
most common lung abnormality seen on HRCT, which was
found in 43 cases (93%), with CT-gg being 1.1  0.9.
In the univariate analysis, all imaging parameters except
CT-gg and wCT-gg scores were significantly associated with
peak systolic PA pressure (see Table 2). Adjustments for age
and sex made little difference to the relationships except for
the normalized MPA measurements, which became insig-
nificant in the multivariate analysis. Interestingly, neither
TLC nor FEV1/FVC ratio were significantly related to peak
systolic PA pressure. However, DLCO and DLCO/VA ratio
(DLCO adjusted for alveolar volume) were both significantly
related to peak systolic PA pressure (Figure 1).
In the stepwise regression model, only 4 variables were
significantly related to the peak systolic PA pressure: wCT-
fib score, DLCO (% predicted), age, and wCT-hc (Table 3).
These 4 variables collectively accounted for 58% of the
variability observed in the peak systolic PA pressure. Of
these, in the present analysis, the wCT-fib score had the
greatest impact, which explained 39% of the variability of
peak systolic PA pressure (P < .0001) (Figure 2).
Discussion
PH is an important complication of scleroderma and is
a leading cause of morbidity and mortality in these patients.
Historically, the MPAD has been used as a CT surrogate for
PA pressure on echocardiography and right heart catheteri-
zation [4e6]. In our cohort, whereas, the peak systolic
pressure on echocardiography does correlate with the MPAD,
our data suggest that the burden of pulmonary fibrosis as
measured by a weighted fibrotic score had the greatest
impact on peak systolic PA pressure. Further, the fibrotic
Table 2
The relationship between peak pulmonary artery pressure and various
imaging and clinical parameters by using multivariate modelling
Parameter
estimate
Univariate
P value
Adjusted
P value
MPAD/BSA 0.02458 .2134 NS
MPAD/AD 0.63986 .0408 .0102
MPAD 0.02737 .0172 .0175
Total perfusion score 0.09081 .0001 <.0001
Weighted total perfusion score 0.08134 .0001 <.0001
Ground glass score 0.08013 .1124 NS
Weighted ground glass score 0.05811 .2193 NS
Fibrotic score 0.20263 <.0001 <.0001
Weighted fibrotic score 0.17786 <.0001 <.0001
Honeycombing score 0.15152 .0397 <.0001
Weighted honeycombing score 0.13049 .0316 .0330
FEV1/FVC 0.00809 .1289 NS
TLC 0.00399 .1213 NS
DLCO (% predicted) 0.00888 <.0001 <.0001
DLCO/VA (% predicted) 0.00530 .0336 .0146
MPAD ¼ main pulmonary artery diameter; BSA ¼ body surface area; NS ¼
not significant; AD ¼ aortic diameter; FEV1 ¼ forced expiratory volume in
1 s; FVC ¼ forced vital capacity; TLC ¼ total lung capacity; DLCO ¼
diffusion capacity of the lung for carbon monoxide; DLCO/VA ¼ DLCO
corrected for alveolar volume.
Table 3
Stepwise regression analysis (SLENTRY ¼ 0.25 and SLSTAY ¼ 0.15),
showing that 4 variables are most predictive of peak pulmonary artery
pressure
Partial
R-square
Model
R-square
Mallow’s
C(p)
P
value
Weighted fibrotic score 0.3888 0.3888 12.6881 <.0001
DLCO (%predicted) 0.0810 0.4698 8.3645 .0246
Age 0.0537 0.5235 6.1757 .0549
Weighted honeycombing score 0.0528 0.5763 4.0575 .0473
DLCO ¼ diffusion capacity of the lung for carbon monoxide.
294 A. K. Pandey et al. / Canadian Association of Radiologists Journal 61 (2010) 291e296score was the single most predictive factor of PH on echo-
cardiography, which suggested that the burden and extent of
pulmonary fibrosis may be helpful in screening patients with
scleroderma for PH.
The pathogenesis of PH in scleroderma is poorly under-
stood. A subset of patients with scleroderma develops PH
without any significant ILD; however, there may be signifi-
cant overlap of ILD with PH in these patients. Although
pulmonary vasculopathy is widely considered to be a major
contributor to PH, the role of pulmonary fibrosis in the
development of PH has not been well described. Previous
autopsy studies described cases of scleroderma, with PH
having significant lung fibrosis without any significant
pulmonary arteriosclerosis [14,15]. A recent study reported
that the lung fibrosis demonstrated on HRCT was an inde-
pendent predictor of PH in patients with scleroderma [16].
We extend the results of this previous study by demonstrating
a severity dependent relationship of the lung fibrosis score
and peak PA pressure as estimated by echocardiography. In
spite of the high degree of correlation between the fibroticFigure 1. Diagram showing a strong negative linear relationship between
peak pulmonary artery (PA) pressure and diffusion capacity of lung for
carbon monoxide (DLCO % of predicted).score and PH, there were patients with significant elevations
in their PA pressure who had minimal or no lung fibrosis.
This suggests that development of PH in scleroderma is
likely multifactorial; in some instances, pulmonary vascul-
opathy, and, in other instances, obliteration of the capillary
bed as a result of lung fibrosis, may be the main contributor.
Several studies previously investigated the association
between MPA diameter and PA pressure and, reported
inconsistent findings [5e19]. One major issue that may
account for this discordance is the heterogeneity (and
suboptimal phenotyping) of the study populations. Zisman et
al [11] studied a homogeneous population of pretransplant
patients of idiopathic pulmonary fibrosis and did not find any
correlation between MPAD or MPAD/AD and PA pressure in
these patients. A recent study, however, showed that MPAD
correlates well with PA pressure in the absence of lung
fibrosis [20]; however, poor correlation was noted in the
setting of fibrosis. In our study, we found statistically
significant correlation between MPAD and peak PA pres-
sures. Our study cohort consisted of a homogeneous pop-
ulation of patients with scleroderma with varying degrees of
lung fibrosis. The extent of lung fibrosis was not severe in the
majority of our cases; in view of the previous study, this may
be one of the explanations why we found significant corre-
lation of MPAD with PA pressure.
Ng et al [21] showed that total lung capacity, a marker of
traction on mediastinal structures, independently affects the
MPA diameter and that MPAD/AD ratio is a better predictor
of PH, particularly in younger patients. In our study, peak PA
pressures were found to correlate slightly better with MPAD/Figure 2. Diagram showing strong linear relationship between peak
pulmonary artery pressure and weighted fibrotic score. A minority of
patients with pulmonary hypertension had no fibrosis.
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not statistically significant. As reported previously, DLCO
was found to have strong negative correlation with PA
pressure [22]; conversely, TLC and FEV1/FVC ratio did not
correlate with PA pressure. Lastly, patient age was found to
be an independent predictor of PH in our series.
Our study had certain limitations. This was a retrospective
study comprising data from a single center. Similar to some
previous studies [9e11,17,19], the CTs were read by a single
chest radiologist; however, we do not think that this biased our
findings, because several previous studies [4,13,21] showed
good interobserver accuracy in measuring MPAD, AD, and
extent of pulmonary fibrosis. As well, although the fibrotic
score is not widely adopted clinically, it is well described in
the medical literature and is quite easily estimated.
Another important limitation of this study is that the PA
pressures were measured by echocardiography, with right heart
catheterization being the criterion standard. The echocardio-
graphic technique that uses the modified Bernoulli equation to
estimate PA systolic pressure on the basis ofmaximum tricuspid
regurgitant (TR) jet velocity is well validated [23e26].
However, some studies reported poor specificity [27,28]. Many
factors may affect the Doppler evaluation of PA pressures. A
technically adequate TRDoppler velocity envelope can only be
obtained in approximately 75% of patients. Care must be taken
to sample the TR jet from multiple windows to ensure axial
alignment of the Doppler cursor with the TR jet and that
a maximal TR velocity is obtained. The technique is dependent
on accurate estimation of right atrial pressure by echocardiog-
raphy. Echo contrast of microbubbles may be used to enhance
the TR signal and increase diagnostic accuracy [29,30]; this
technique was not used in our study. All the cases, however,
were read by a single level-3 echocardiographer, and only those
studies in which an accurate estimate of PA pressure was
obtained were included.
According to current clinical practice, the only patients
with scleroderma likely to undergo right heart catheterization
are those suspected to have PH on the basis of clinical and
echocardiographic data. Hence, a study that includes only
patients who have been subjected to right heart catheteriza-
tion is likely to contain inherent selection bias. Accordingly,
results of such a study could not be considered representative
of the general population of patients with scleroderma. Our
study cohort was arguably more representative of patients
with scleroderma in general.
Our study is cross sectional in design, and, although it
shows a strong correlation between burden of lung fibrosis
and PA pressure, a cause-and-effect relationship cannot be
inferred. The question as to whether lung fibrosis plays
a causal role in the development of PH needs to be further
investigated with longitudinal studies.
Conclusion
In our cohort of 46 patients with a known diagnosis of
scleroderma, the single greatest predictor of PH was the
burden of fibrosis as determined by a weighted fibrotic score.Hence, severity and extent of pulmonary fibrosis as deter-
mined by HRCT may be helpful in screening for PH in
patients with SSc. Radiologists should consider incorpo-
rating fibrotic scoring into their clinical reports to help
enable an earlier and more accurate diagnosis of PH with CT
in patients with scleroderma.References
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